Clik here to view.
Cullgen Announces Series Seed Financing
TOKYO Cullgen Inc. announced a Series Seed Financing of up to $15M by GNI Group Ltd. (GNIG) (TOKYO: 2160) to build a new drug discovery platform based on advanced ubiquitin-mediated protein...
View ArticleClik here to view.
ABEC推出面向生物制药行业的大规模单次使用微生物发酵解决方案
宾夕法尼亚州伯利恒 (美国商业资讯) — 全球领先的生物制药制造一体化解决方案及服务提供商ABEC今天发布了大规模单次使用微生物发酵能力。ABEC的CSR技术展现了一流性能，工作容量最高达1,000升。...
View ArticleClik here to view.
Britons risk permanent hearing damage for enjoyment
LONDON An alarming number of Britons are intentionally exposing themselves to dangerous levels of noise, risking permanent hearing loss, simply to increase their enjoyment of an experience such as...
View ArticleClik here to view.
Octapharma集团发布2017年年报，公司实现了17.2亿欧元的营收，3.49亿欧元的运营收入
瑞士拉亨 (美国商业资讯)–过去六年间，Octapharma集团达到15%的惊人年复合增长率，2017年年报再次显示破纪录的财务结果，销售额达17.2亿欧元，与2016年相比增加1.2亿欧元（7.5%）（以固定货币为基础，增速为9.4%）。...
View ArticleClik here to view.
インドの有力な腎臓病治療センターが連続的治療過程にマシモの技術を採用
印バンガロール （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、インドの有力な腎臓病治療センターであるNU Hospitalsが、連続的治療過程にマシモの技術を標準として採用したと発表しました。NU Hospitalsはマシモと戦略的提携契約を結び、バンガロールにある同病院の2施設で、手術室（OR）、集中治療室（ICU）、透析ベッド、一般病棟にマシモの技術を採用しました。...
View ArticleClik here to view.
オクタファルマ・グループが2017年業績を発表：17億2000万ユーロの売上高と3億4900万ユーロの営業利益を計上
スイス・ラーヘン （ビジネスワイヤ） — オクタファルマ・グループは過去6年間にわたり、15%という見事な年平均成長率を達成し、さらに2017年も記録を更新して売上高17億2000万ユーロの業績を計上しました。この売上高は2016年より1億2000万ユーロの増加（7.5%増）（恒常通貨ベースの成長率は9.4%）となります。...
View ArticleClik here to view.
Certara社がVirtual Twin™テクノロジーのPoCを発表
ニュージャージー州プリンストン （ビジネスワイヤ） — モデルを活かした医薬品開発とレギュラトリー・サイエンスの分野で世界をリードするCertara®社は、Virtual Twin™テクノロジーのProof of Concept（PoC）を示す2本の論文を発表したことを本日公表いたしました。 「当社のVirtual...
View ArticleClik here to view.
Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in...
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with epidermal growth factor receptor...
View ArticleClik here to view.
Fifty-Two Week Safety Study on Symproic® (naldemedine) for Opioid-induced...
OSAKA, Japan & FLORHAM PARK, N.J. & STAMFORD, Conn. Shionogi Inc. and Purdue Pharma L.P. today announced the publication of a study known as COMPOSE-3. The study is the first to investigate...
View ArticleClik here to view.
Synergy Biomedical Announces Regulatory Clearance and Launch of BIOSPHERE...
COLLEGEVILLE, Pa. Synergy Biomedical, LLC, a developer of orthobiologic and biomaterial products, announced that it has received Therapeutic Goods Administration (TGA) clearance in Australia for its...
View ArticleClik here to view.
Second Sight Medical Products, Inc. to Present at the B. Riley & Co. China...
SYLMAR, Calif. Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to...
View ArticleClik here to view.
AmpliPhi Biosciences Announces Presentation of Preclinical Data Demonstrating...
SAN DIEGO AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections,...
View ArticleClik here to view.
Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing &...
CAMBRIDGE, Mass. Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough,...
View ArticleClik here to view.
New Study Investigates the Performance of Masimo SpHb® During Acute Bleeding...
NEUCHATEL, Switzerland Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Cairo University in Egypt evaluated the accuracy and trending of...
View ArticleClik here to view.
The Engaged Database (TED), a Benchmark Sample of Anonymised Clinical Study...
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 MUNICH The Engaged Database (TED) allows users to compare their own audit observations, against a large number of other audit results,...
View ArticleClik here to view.
Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel...
TOKYO & LONDON Sosei Group (“Sosei” or the “Company”; TOKYO Mothers Index: 4565), the world leader in GPCR medicine design and development, announced that it has regained worldwide rights from...
View ArticleClik here to view.
サンバイオと日立化成：再生医療等製品「SB623」の製造に関する業務提携に合意
東京 （ビジネスワイヤ） – サンバイオグループ（本社：東京都中央区、社長：森 敬太、以下「サンバイオ」）と日立化成株式会社（本社：東京都千代田区、執行役社長：丸山 寿、以下「日立化成」）は、この度サンバイオと、日立化成の子会社で再生医療等製品*1の受託製造事業を行うHitachi Chemical Advanced Therapeutics Solutions,...
View ArticleClik here to view.
SanBio Reaches Agreement on Manufacture of Regenerative Medicine Product...
TOKYO SanBio Group and Hitachi Chemical Co., Ltd. (Hitachi Chemical) jointly announced today that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS; formerly...
View ArticleClik here to view.
PAREXEL and CHA Medical Group Partner to Enhance Early Phase Clinical...
BOSTON PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today announced an alliance with CHA Medical Group (CHA) to enhance early phase clinical...
View ArticleClik here to view.
新研究调查急性出血期间和补液复苏后Masimo SpHb®的性能
瑞士纳沙泰尔 (美国商业资讯) — Masimo (NASDAQ: MASI)今天发布了近期发表的一项研究结果，在该研究中，埃及开罗大学研究人员评估了急性出血期间和补液复苏后 Masimo血红蛋白无创连续测定(SpHb®)相对于血红蛋白创伤性实验室测定(Lab-Hb)的精度和趋势1。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View Article